FHIR IG analytics| Package | hl7.fhir.uv.ebm |
| Resource Type | Citation |
| Id | Citation-179625.json |
| FHIR Version | R6 |
No resources found
No resources found
Note: links and images are rebased to the (stated) source
Generated Narrative: Citation 179625
version: 18; Last updated: 2025-10-13 12:34:35+0000
Profile: JournalArticleCitation
ArtifactPublicationStatus: Active
identifier: FEvIR Object Identifier/179625, https://pubmed.ncbi.nlm.nih.gov/22502942, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.5
version: 1.0.0-ballot3
title: 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
status: Active
date: 2026-02-10 14:00:26+0000
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description:
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| Citation Classification Type: fevir-platform-use (FEvIR Platform Use) | Medline Base |
jurisdiction: World
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2012-12-07
lastReviewDate: 2022-03-10
classification
type: Citation Source
classifier: MEDLINE
classification
type: MEDLINE Citation Owner
classifier: National Library of Medicine, Index Section
currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish
statusDate
activity: PubMed Pubstatus of Received
period: ?? --> 2012-02-03
statusDate
activity: PubMed Pubstatus of Accepted
period: ?? --> 2012-03-23
statusDate
activity: PubMed Pubstatus of Entrez
period: ?? --> 2012-04-17 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Pubmed
period: ?? --> 2012-04-17 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline
period: ?? --> 2012-12-12 06:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/22502942,https://doi.org/10.1016/j.eururo.2012.03.053, pii/S0302-2838(12)00425-3Titles
Type Text Primary title Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
Abstracts
Type Text Copyright Primary human use BACKGROUND: Radiotherapy combined with androgen-deprivation therapy (ADT) is superior to radiotherapy alone in localised prostate cancer; however, data comparing ADT alone are somewhat limited. OBJECTIVE: To compare 3-yr ADT plus radiotherapy with ADT alone in locally advanced prostate cancer patients. DESIGN, SETTING, AND PARTICIPANTS: A multicentre randomised open controlled phase 3 trial in 264 histologically confirmed T3-4 or pT3N0M0 prostate cancer patients randomised from March 2000 to December 2003. INTERVENTION: ADT (11.25mg subcutaneous depot injection of leuprorelin every 3 mo for 3 yr) plus external-beam radiotherapy or ADT alone. Flutamide (750 g/d) was administered for 1 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary objective was 5 yr progression-free survival (PFS) according to clinical or biologic criteria, using the American Society for Therapeutic Radiology and Oncology (ASTRO) and the newer (Phoenix) definition (nadir plus 2 ng/ml), by intention to treat. Secondary objectives included time to locoregional recurrence and distant metastases, and overall and disease-specific survival. Our Analyses: intent-to-treat analysis, multivariate analyses using a Cox model with a 5% threshold from univariate analysis, and Kaplan-Meier estimates. RESULTS AND LIMITATIONS: ADT alone was administered to 130 patients and combined therapy to 133. With a median follow-up of 67 mo, 5-yr PFS was 60.9% for combined therapy versus 8.5% with ADT alone (ASTRO; p<0.0001), and 64.7% versus 15.4%, respectively, for Phoenix (p<0.0011). Locoregional progression was reported in 9.8% of combined-therapy patients versus 29.2% with ADT alone (p<0.0001) and metastatic progression in 3.0% versus 10.8%, respectively (p<0.018). Overall survival was 71.4% with combined therapy versus 71.5% with ADT alone; disease-specific survival was 93.2% versus 86.2%. Limitations included the relatively small population and a relatively short follow-up period. CONCLUSIONS: Combined therapy strongly favoured improved PFS, locoregional control, and metastasis-free survival. Longer follow-up is needed to assess the potential survival impact.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
RelatesTos
Type Classifier Citation Has Comment In Comment Eur Urol. 2012 Aug;62(2):220-1; author reply 222-3. doi: 10.1016/j.eururo.2012.04.040.
publicationForm
publishedIn
type: Periodical
identifier: Electronic ISSN Type/1873-7560, ISOAbbreviation/Eur Urol, ISSN Linking/0302-2838, Medline Title Abbreviation/Eur Urol, NLM Unique ID/7512719
title: European urology
publisherLocation: Switzerland
citedMedium: Internet
volume: 62
issue: 2
articleDate: 2012-08
pageString: 213-9
publicationForm
citedMedium: Internet without issue
articleDate: 2012-04-03
webLocation
classifier: Abstract
webLocation
classifier: DOI Based
classification
type: Publishing Model
classifier: Print Electronic
classification
type: Chemical
classifier: Androgen Antagonists, Antineoplastic Agents, Hormonal, Flutamide, Prostate-Specific Antigen, Leuprolide
classification
type: MeSH heading
artifactAssessment: ArtifactAssessment: artifact[x] = this resource
classification
type: Publication type
classifier: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
classification
type: Knowledge Artifact Type
classifier: Journal Article
artifactAssessment: Classifier added by Computable Publishing LLC
classification
type: Citation subset
classifier: IM
contributorship
complete: true
entry
contributor: Mottet N
forenameInitials: N
affiliation: Department of Urology, University Hospital, St. Etienne, France. nicolas.mottet@wanadoo.fr
entry
contributor: Peneau M
forenameInitials: M
entry
contributor: Mazeron JJ
forenameInitials: JJ
entry
contributor: Molinie V
forenameInitials: V
entry
contributor: Richaud P
forenameInitials: P
Generated Narrative: Practitioner #contributor0
name: Nicolas Mottet
Generated Narrative: Practitioner #contributor1
name: Michel Peneau
Generated Narrative: Practitioner #contributor2
name: Jean-Jacques Mazeron
Generated Narrative: Practitioner #contributor3
name: Vincent Molinie
Generated Narrative: Practitioner #contributor4
name: Pierre Richaud
Generated Narrative: ArtifactAssessment #meshHeading0
content
type: components (if present) include qualifier codings
classifier: Adenocarcinoma
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic No component
type: qualifier
classifier: radiotherapy
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapy
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Androgen Antagonists
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Antineoplastic Agents, Hormonal
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Chemoradiotherapy
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Disease-Free Survival
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Drug Therapy, Combination
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Flutamide
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Humans
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Leuprolide
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: therapeutic use
Components
Type Classifier is Major topic Yes content
type: components (if present) include qualifier codings
classifier: Male
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Middle Aged
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Neoplasm Grading
freeToShare: true
Components
Type Classifier qualifier is not a major topic content
type: components (if present) include qualifier codings
classifier: Prostate-Specific Antigen
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: blood
Components
Type Classifier is Major topic No content
type: components (if present) include qualifier codings
classifier: Prostatic Neoplasms
freeToShare: true
component
type: qualifier
classifier: is not a major topic
component
type: qualifier
classifier: drug therapy
Components
Type Classifier is Major topic No component
type: qualifier
classifier: radiotherapy
Components
Type Classifier is Major topic No component
type: qualifier
classifier: therapy
Components
Type Classifier is Major topic Yes
FHIR
FHIRsmith{
"resourceType": "Citation",
"id": "179625",
"meta": {
"versionId": "18",
"lastUpdated": "2025-10-13T12:34:35.118Z",
"profile": [
"http://hl7.org/fhir/uv/ebm/StructureDefinition/journal-article-citation"
]
},
"text": {
"status": "extensions",
"div": "<!-- snip (see above) -->"
},
"contained": [
{
"resourceType": "Practitioner",
"id": "contributor0",
"name": [
{
"family": "Mottet",
"given": [
"Nicolas"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor1",
"name": [
{
"family": "Peneau",
"given": [
"Michel"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor2",
"name": [
{
"family": "Mazeron",
"given": [
"Jean-Jacques"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor3",
"name": [
{
"family": "Molinie",
"given": [
"Vincent"
]
}
]
},
{
"resourceType": "Practitioner",
"id": "contributor4",
"name": [
{
"family": "Richaud",
"given": [
"Pierre"
]
}
]
},
{
"resourceType": "ArtifactAssessment",
"id": "meshHeading0",
"artifactReference": {
"reference": "#",
"type": "Citation"
},
"content": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000230",
"display": "Adenocarcinoma",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000188",
"display": "drug therapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000532",
"display": "radiotherapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000628",
"display": "therapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000368",
"display": "Aged",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000726",
"display": "Androgen Antagonists",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D018931",
"display": "Antineoplastic Agents, Hormonal",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D059248",
"display": "Chemoradiotherapy",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D018572",
"display": "Disease-Free Survival",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D004359",
"display": "Drug Therapy, Combination",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D005485",
"display": "Flutamide",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D006801",
"display": "Humans",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016729",
"display": "Leuprolide",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000627",
"display": "therapeutic use"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D008297",
"display": "Male",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D008875",
"display": "Middle Aged",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D060787",
"display": "Neoplasm Grading",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D017430",
"display": "Prostate-Specific Antigen",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000097",
"display": "blood"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
],
"text": "components (if present) include qualifier codings"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D011471",
"display": "Prostatic Neoplasms",
"userSelected": false
}
]
}
],
"freeToShare": true,
"component": [
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"text": "is not a major topic"
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000188",
"display": "drug therapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000532",
"display": "radiotherapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49487",
"display": "No"
}
]
}
]
}
]
},
{
"type": {
"text": "qualifier"
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "Q000628",
"display": "therapy"
}
]
}
],
"component": [
{
"type": {
"text": "is Major topic"
},
"classifier": [
{
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C49488",
"display": "Yes"
}
]
}
]
}
]
}
]
}
]
}
],
"extension": [
{
"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
"code": "active",
"display": "Active"
}
]
}
}
],
"url": "https://fevir.net/resources/Citation/179625",
"identifier": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "FEvIR Object Identifier"
},
"system": "https://fevir.net/FOI",
"value": "179625",
"assigner": {
"display": "Computable Publishing LLC"
}
},
{
"system": "https://pubmed.ncbi.nlm.nih.gov",
"value": "22502942"
},
{
"system": "urn:ietf:rfc:3986",
"value": "urn:oid:2.16.840.1.113883.4.642.40.44.15.5"
}
],
"version": "1.0.0-ballot3",
"title": "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.",
"status": "active",
"date": "2026-02-10T14:00:26+00:00",
"author": [
{
"name": "Computable Publishing®: MEDLINE-to-FEvIR Converter"
}
],
"publisher": "HL7 International / Clinical Decision Support",
"contact": [
{
"name": "HL7 International / Clinical Decision Support",
"telecom": [
{
"system": "url",
"value": "http://www.hl7.org/Special/committees/dss"
}
]
}
],
"description": "This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
"useContext": [
{
"code": {
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "fevir-platform-use",
"display": "FEvIR Platform Use"
},
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "medline-base",
"display": "Medline Base",
"userSelected": false
}
]
}
}
],
"jurisdiction": [
{
"coding": [
{
"system": "http://unstats.un.org/unsd/methods/m49/m49.htm",
"code": "001",
"display": "World"
}
]
}
],
"copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/",
"approvalDate": "2012-12-07",
"lastReviewDate": "2022-03-10",
"classification": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "citation-source",
"display": "Citation Source"
}
]
},
"classifier": [
{
"text": "MEDLINE"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-classification-type",
"code": "medline-owner",
"display": "MEDLINE Citation Owner"
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#owner_value",
"code": "NLM",
"display": "National Library of Medicine, Index Section",
"userSelected": false
}
]
}
]
}
],
"currentState": [
{
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "medline-medline",
"display": "Medline Citation Status of Medline"
}
]
},
{
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-publication-status-ppublish",
"display": "PubMed PublicationStatus of ppublish"
}
]
}
],
"statusDate": [
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-received",
"display": "PubMed Pubstatus of Received"
}
]
},
"period": {
"end": "2012-02-03"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-accepted",
"display": "PubMed Pubstatus of Accepted"
}
]
},
"period": {
"end": "2012-03-23"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-entrez",
"display": "PubMed Pubstatus of Entrez"
}
]
},
"period": {
"end": "2012-04-17T06:00:00.000Z"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-pubmed",
"display": "PubMed Pubstatus of Pubmed"
}
]
},
"period": {
"end": "2012-04-17T06:00:00.000Z"
}
},
{
"activity": {
"coding": [
{
"system": "http://hl7.org/fhir/citation-status-type",
"code": "pubmed-pubstatus-medline",
"display": "PubMed Pubstatus of Medline"
}
]
},
"period": {
"end": "2012-12-12T06:00:00.000Z"
}
}
],
"citedArtifact": {
"identifier": [
{
"system": "https://pubmed.ncbi.nlm.nih.gov",
"value": "22502942"
},
{
"system": "https://doi.org",
"value": "10.1016/j.eururo.2012.03.053"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "ACSN",
"display": "Accession ID"
}
],
"text": "pii"
},
"value": "S0302-2838(12)00425-3"
}
],
"title": [
{
"type": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/title-type",
"code": "primary",
"display": "Primary title"
}
]
}
],
"text": "Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial."
}
],
"abstract": [
{
"type": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-abstract-type",
"code": "primary-human-use",
"display": "Primary human use"
}
]
}
],
"text": "**BACKGROUND:** Radiotherapy combined with androgen-deprivation therapy (ADT) is superior to radiotherapy alone in localised prostate cancer; however, data comparing ADT alone are somewhat limited.\n**OBJECTIVE:** To compare 3-yr ADT plus radiotherapy with ADT alone in locally advanced prostate cancer patients.\n**DESIGN, SETTING, AND PARTICIPANTS:** A multicentre randomised open controlled phase 3 trial in 264 histologically confirmed T3-4 or pT3N0M0 prostate cancer patients randomised from March 2000 to December 2003.\n**INTERVENTION:** ADT (11.25mg subcutaneous depot injection of leuprorelin every 3 mo for 3 yr) plus external-beam radiotherapy or ADT alone. Flutamide (750 g/d) was administered for 1 mo.\n**OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:** The primary objective was 5 yr progression-free survival (PFS) according to clinical or biologic criteria, using the American Society for Therapeutic Radiology and Oncology (ASTRO) and the newer (Phoenix) definition (nadir plus 2 ng/ml), by intention to treat. Secondary objectives included time to locoregional recurrence and distant metastases, and overall and disease-specific survival. Our Analyses: intent-to-treat analysis, multivariate analyses using a Cox model with a 5% threshold from univariate analysis, and Kaplan-Meier estimates.\n**RESULTS AND LIMITATIONS:** ADT alone was administered to 130 patients and combined therapy to 133. With a median follow-up of 67 mo, 5-yr PFS was 60.9% for combined therapy versus 8.5% with ADT alone (ASTRO; p<0.0001), and 64.7% versus 15.4%, respectively, for Phoenix (p<0.0011). Locoregional progression was reported in 9.8% of combined-therapy patients versus 29.2% with ADT alone (p<0.0001) and metastatic progression in 3.0% versus 10.8%, respectively (p<0.018). Overall survival was 71.4% with combined therapy versus 71.5% with ADT alone; disease-specific survival was 93.2% versus 86.2%. Limitations included the relatively small population and a relatively short follow-up period.\n**CONCLUSIONS:** Combined therapy strongly favoured improved PFS, locoregional control, and metastasis-free survival. Longer follow-up is needed to assess the potential survival impact.",
"copyright": "Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved."
}
],
"relatesTo": [
{
"type": "comment-in",
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016420",
"display": "Comment",
"userSelected": false
}
]
}
],
"citation": "Eur Urol. 2012 Aug;62(2):220-1; author reply 222-3. doi: 10.1016/j.eururo.2012.04.040."
}
],
"publicationForm": [
{
"publishedIn": {
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/published-in-type",
"code": "D020492",
"display": "Periodical"
}
]
},
"identifier": [
{
"type": {
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#issn",
"code": "Electronic",
"display": "Electronic"
}
],
"text": "Electronic ISSN Type"
},
"system": "https://portal.issn.org",
"value": "1873-7560"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "ISOAbbreviation"
},
"system": "https://www.issn.org/services/online-services/access-to-the-ltwa/",
"value": "Eur Urol"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "ISSN Linking"
},
"system": "https://www.issn.org/understanding-the-issn/assignment-rules/the-issn-l-for-publications-on-multiple-media/",
"value": "0302-2838"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "Medline Title Abbreviation"
},
"system": "https://www.nlm.nih.gov/tsd/cataloging/contructitleabbre.html",
"value": "Eur Urol"
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/v2-0203",
"code": "XX",
"display": "Organization identifier"
}
],
"text": "NLM Unique ID"
},
"system": "https://locatorplus.gov/cgi-bin/Pwebrecon.cgi?DB=local",
"value": "7512719"
}
],
"title": "European urology",
"publisherLocation": "Switzerland"
},
"citedMedium": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-medium",
"code": "internet",
"display": "Internet"
}
]
},
"volume": "62",
"issue": "2",
"articleDate": "2012-08",
"pageString": "213-9"
},
{
"citedMedium": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-medium",
"code": "internet-without-issue",
"display": "Internet without issue"
}
]
},
"articleDate": "2012-04-03"
}
],
"webLocation": [
{
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code": "abstract",
"display": "Abstract"
}
]
}
],
"url": "https://pubmed.ncbi.nlm.nih.gov/22502942/"
},
{
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-url-classifier",
"code": "doi-based",
"display": "DOI Based"
}
]
}
],
"url": "https://doi.org/10.1016/j.eururo.2012.03.053"
}
],
"classification": [
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "publishing-model",
"display": "Publishing Model",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "Print-Electronic",
"display": "Print Electronic",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "chemical",
"display": "Chemical",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D000726",
"display": "Androgen Antagonists",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D018931",
"display": "Antineoplastic Agents, Hormonal",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.cas.org/support/documentation/chemical-substances",
"code": "76W6J0943E",
"userSelected": false
},
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D005485",
"display": "Flutamide",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.cas.org/support/documentation/chemical-substances",
"code": "EC 3.4.21.77",
"userSelected": false
},
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D017430",
"display": "Prostate-Specific Antigen",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.cas.org/support/documentation/chemical-substances",
"code": "EFY6W0M8TG",
"userSelected": false
},
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016729",
"display": "Leuprolide",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "mesh-heading",
"display": "MeSH heading"
}
]
},
"artifactAssessment": [
{
"reference": "#meshHeading0",
"type": "ArtifactAssessment"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "publication-type",
"display": "Publication type"
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D017428",
"display": "Clinical Trial, Phase III",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016428",
"display": "Journal Article",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016448",
"display": "Multicenter Study",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D016449",
"display": "Randomized Controlled Trial",
"userSelected": false
}
]
},
{
"coding": [
{
"system": "https://www.nlm.nih.gov/mesh",
"code": "D013485",
"display": "Research Support, Non-U.S. Gov't",
"userSelected": false
}
]
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "knowledge-artifact-type",
"display": "Knowledge Artifact Type",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/citation-artifact-classifier",
"code": "D016428",
"display": "Journal Article",
"userSelected": false
}
]
}
],
"artifactAssessment": [
{
"display": "Classifier added by Computable Publishing LLC"
}
]
},
{
"type": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/cited-artifact-classification-type",
"code": "citation-subset",
"display": "Citation subset",
"userSelected": false
}
]
},
"classifier": [
{
"coding": [
{
"system": "https://www.nlm.nih.gov/bsd/licensee/elements_descriptions.html#citationsubset",
"code": "IM",
"display": "IM",
"userSelected": false
}
]
}
]
}
],
"contributorship": {
"complete": true,
"entry": [
{
"contributor": {
"reference": "#contributor0",
"type": "Practitioner",
"display": "Mottet N"
},
"forenameInitials": "N",
"affiliation": [
{
"display": "Department of Urology, University Hospital, St. Etienne, France. nicolas.mottet@wanadoo.fr"
}
]
},
{
"contributor": {
"reference": "#contributor1",
"type": "Practitioner",
"display": "Peneau M"
},
"forenameInitials": "M"
},
{
"contributor": {
"reference": "#contributor2",
"type": "Practitioner",
"display": "Mazeron JJ"
},
"forenameInitials": "JJ"
},
{
"contributor": {
"reference": "#contributor3",
"type": "Practitioner",
"display": "Molinie V"
},
"forenameInitials": "V"
},
{
"contributor": {
"reference": "#contributor4",
"type": "Practitioner",
"display": "Richaud P"
},
"forenameInitials": "P"
}
]
}
}
}